Cambridge Healthtech Institute’s Sixth Annual
Engineering Bispecific Antibodies
Harnessing Complexity
Part of the 11th Annual PEGS: the essential protein engineering summit
May 7-8, 2015 | World Trade Center | Boston, Massachusetts


This conference will highlight different approaches to bispecific antibody constructs and reveal key elements for efficacy and drug-like properties. Disease areas beyond oncology will be reviewed, such as ophthalmology, infectious disease, and inflammatory diseases. Aspects for enhancement such as purification, stability, neutralization, enhanced targeting, modulating immune response, expression, characterization, improvements in humanization and clearance will be considered.

CREATING THE NEXT WAVE OF BISPECIFICS 

KEYNOTE PRESENTATION: Creating a Wide Variety of Nanoparticles, Antibody-Drug Conjugates and Bispecific Antibodies

Ulrich B. Nielsen, Ph.D., CSO & Senior Vice President, Merrimack Pharmaceuticals

Talk Title to be Announced 

Trevor J. Hallam, Ph.D., CSO, Sutro Biopharma

New Platform for scFv-Based Bispecifics

G. Jonah Rainey, Ph.D., Senior Scientist, ADPE, MedImmune, LLC

High-Throughput Design, Production, and Evaluation of Bispecific Antibodies

Maria Wendt, Ph.D., Senior Scientific Consultant, Biologics, Genedata

 

DELIVERY ACROSS BBB 

A Novel Platform for Engineering Blood-Brain Barrier-Crossing Bispecific Biologics

Graham Farrington, Ph.D., Director, Protein & Antibody Engineering, Biogen

Functional Characterization of Blood-Brain Barrier-Crossing Antibodies

Danica B. Stanimirovic, M.D., Ph.D., Director, R&D, Translational Bioscience, Human Health Therapeutics Portfolio, National Research Council of Canada

Recent BBB Transport Efforts in Cyno Using an Affinity Engineered Anti-Tfr/BACE1 Bispecific

Mark S. Dennis, Ph.D., Principal Scientist, Genentech, Inc.

 

APPLICATIONS OUTSIDE OF ONCOLOGY 

Many Birds, One Stone: Discovering Multi-Specific mAbs for Infectious Diseases

Eszter Nagy, M.D., Ph.D., CSO, President, Arsanis, Inc.

Anti-Infective Bispecific Antibodies for Viral Infections

Paul MacAry, Ph.D., Associate Professor, Microbiology, National University of Singapore

 

NEW METHODS FOR GENERATING BISPECIFIC ANTIBODIES 

What Unique Properties Do They Have for Solving Problems?

FIT-Ig: A Novel Bispecific Antibody Format Combining Any Two mAbs into One Bi-Functional Ig Molecule

Robert Kamen, Ph.D., Epimab Biotherapeutics

Designing and Discovering Transformative Bispecific Antibody Therapeutics

Martin Steegmaier, Ph.D., MBA, Head, Discovery, Large Molecule Research & Early Development (pRED), Roche Innovation Center Penzberg GmbH

Bispecific Fynomabs: Novel Mode-of-Action through Tailored Architecture

Simon Brack, Ph.D., Director, Discovery Research, Covagen AG

Facile Generation of Common Light Chain Bispecific Antibodies

Eric M. Krauland, Ph.D., Senior Director, Antibody Discovery and Optimization, Adimab LLC

Bispecific Antibodies against HIV-1 and Cancer-Related Proteins

Dimiter S. Dimitrov, Ph.D., Senior Investigator, Experimental Immunology Laboratory, National Cancer Institute, NIH

T Cell Engaging Technology

Annelise Vuidepot, Ph.D., Head, Protein Science, Immunocore Ltd.

Optimization and Application of an Fc-Containing Bispecific Platform

John R. Desjarlais, Ph.D., CSO, Xencor, Inc.

Talk Title to be Announced 

Carlo Boutton, Ph.D., Director, Technology & Information Management, Ablynx nv